Actinium Provides Up
Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting
June 25, 2018 16:15 ET | Actinium Pharmaceuticals
Two Nuclear Medicine focused advisory boards have been formed to provide expertise and strategic guidance to Actinium  Meeting with Iomab-B and Actimab investigators to be held to provide trial...
Actinium Pharmaceuti
Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
March 28, 2018 08:00 ET | Actinium Pharmaceuticals
- Collaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents  - Actinium to perform preclinical...
Actinium Pharmaceuti
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
March 14, 2018 07:30 ET | Actinium Pharmaceuticals
Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or...
Actinium Pharmaceuti
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
February 05, 2018 16:15 ET | Actinium Pharmaceuticals
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...
Actinium Pharmaceuti
Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster Product
February 01, 2018 07:30 ET | Actinium Pharmaceuticals
- Poster to present additional data showcasing ability of Actinium’s AWE Technology to yield a potential biobetter of daratumumab, a blockbuster CD38 targeted therapy for multiple myeloma NEW YORK,...
Actinium Pharmaceuti
Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs
January 08, 2018 07:30 ET | Actinium Pharmaceuticals
- Dr. Ludwig brings over 20 years of leadership and management expertise from Eli Lilly and Company and Imclone Systems, Inc. in oncology antibody therapeutics discovery and development where he...
Actinium Pharmaceuti
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M
December 11, 2017 16:15 ET | Actinium Pharmaceuticals
Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for...
Actinium Pharmaceuti
Actinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual Meeting
December 11, 2017 06:30 ET | Actinium Pharmaceuticals
69% Overall Response Rate and 98% median reduction in bone marrow blasts reported with Actimab-A given at 2.0 µCi/kg/fraction as a single agent Minimal extramedullary toxicities observed; No evidence...
Actinium Pharmaceuti
Actinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail Roboz
November 13, 2017 07:30 ET | Actinium Pharmaceuticals
- Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian will introduce the planned clinical initiative on the webcast  -...
Actinium Pharmaceuti
Actinium Pharmaceuticals to Present at BIO Investor Forum
October 16, 2017 07:30 ET | Actinium Pharmaceuticals
- Actinium to present on Tuesday, October 17th at 3 PM PT NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...